BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32878799)

  • 1. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Ishii A; Shigemura K; Kitagawa K; Sung SY; Chen KC; Yi-Te C; Liu MC; Fujisawa M
    Anticancer Res; 2020 Sep; 40(9):5107-5114. PubMed ID: 32878799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
    Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
    Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
    Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
    Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
    Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
    Maughan BL; Suzman DL; Luber B; Wang H; Glavaris S; Hughes R; Sullivan R; Harb R; Boudadi K; Paller C; Eisenberger M; Demarzo A; Ross A; Antonarakis ES
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1297-1304. PubMed ID: 27826729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
    Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
    Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
    Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
    Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
    Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma.
    Cho K; Moon H; Seo SH; Ro SW; Kim BK
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
    Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
    FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression.
    Kitagawa K; Shigemura K; Sung SY; Chen KC; Huang CC; Chiang YT; Liu MC; Huang TW; Yamamichi F; Shirakawa T; Fujisawa M
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2261-2271. PubMed ID: 31367836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.